Winda Fung

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Cooley advised PetIQ (Nasdaq: PETQ), a leading pet medication, health and wellness company, on its definitive merger agreement with Bansk Group, pursuant to which Bansk Group will acquire all outstanding shares of PetIQ’s common stock for $31 per share in an all-cash transaction valued at approximately $1.5 billion.

Cooley advised Tetra Tech, a leading global provider of consulting and engineering services that focuses on water, environment, sustainable infrastructure, renewable energy and international development, on its Rule 144A offering of $575 million aggregate principal amount of 2.25% convertible senior notes due 2028, which includes the full exercise of the initial purchasers’ option to purchase an additional $75 million aggregate principal amount of notes. Partners John-Paul Motley, Mischi a Marca, Jason Savich, Ellie Guadiana and Logan Tiari led the Cooley team advising Tetra Tech.

Cooley advised Ionis Pharmaceuticals, a biotechnology company, in its $575 million aggregate principal amount of convertible senior notes.

Cooley advised Mirum Pharmaceuticals on its $275 million aggregate principal amount of 4.00% convertible senior notes due 2029. Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Jason Kent and Jason Savich led the Cooley team.